MetaCap

Arrowhead Pharmaceuticals Inc. (ARWR)

NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

41.37-2.28 (-5.22%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ARWR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.11
52-week range
40.43 – 95.49
Day range
41.17 – 44.80
Volume / Avg
3.91M / 2.08M
Beta
—
Next earnings
Nov 24, 2026

52-week range

$40.43$95.49

ARWR stock today

Arrowhead Pharmaceuticals (ARWR) closed at $41.37 on Nov 20, down 5.22% (-$2.28), versus the S&P 500's 3.70% decline. At this level, ARWR sits near the bottom of its 52-week range of $40.43 to $95.49: 56.7% below the high, set on Jul 22, 2026 and 2.3% above the low. ARWR is down 37.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 2.3%.

Arrowhead Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$5.11), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 24; analysts expect EPS of -$1.59.

Summary generated from market data by MetaCap's automated system. Methodology

About Arrowhead Pharmaceuticals

Company profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Christopher R. Anzalone Ph.D.
Headquarters
Pasadena, CA
Employees
1,062

Financial highlights

Full financials

In fiscal 2026, Arrowhead Pharmaceuticals generated $450.8 million in revenue, down 45.6% from fiscal 2025, its first annual decline since 2024. Arrowhead Pharmaceuticals reported a net loss of $724.2 million, compared with a loss of $1.6 million a year earlier. Operating margin was -156.9%.

Arrowhead Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$450.82M$829.45M$3.55M$240.74M$243.23M
Growth-45.65%+23258.15%-98.52%-1.03%+75.89%
Net income$-724.21M$-1.63M$-599.49M$-205.28M$-176.06M
EPS (diluted)$-5.11$-0.01$-5.00$-1.92$-1.67

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$106.07+156.39%

  • Strong buy 4
  • Buy 10
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $73.00High $126.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 24, 2026
EPS estimate
$-1.59
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-3.04 vs $-1.59
Surprise
-91.19%

ARWR news

All ARWR news

Arrowhead Pharmaceuticals peers

Health Care sector
ARWR peer companies
CompanyPrice% ChgMarket capCompare
SUPNSupernus Inc.28.61+0.92%$5.94Bvs ARWR
LGNDLigand Pharmaceuticals Incorporated286.85-0.03%$5.74Bvs ARWR
GRFSGrifols S.A. ADR8.15-0.61%$5.55Bvs ARWR
MIRMMirum Pharmaceuticals Inc.96.13+0.65%$6.28Bvs ARWR
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs ARWR
BLTEBelite Bio Inc ADR127.38-15.65%$5.17Bvs ARWR
MANEVeradermics Incorporated119.52-3.92%$5.04Bvs ARWR
LQDALiquidia Corporation54.43-3.88%$4.90Bvs ARWR

Indexes, lists and sector

Arrowhead Pharmaceuticals stock FAQ

What is Arrowhead Pharmaceuticals's stock price today?

ARWR last traded at $41.37 as of Nov 20, 4:00 PM EST, down 5.22% on the day. Prices are delayed at least 15 minutes.

Does Arrowhead Pharmaceuticals pay a dividend?

No. Arrowhead Pharmaceuticals does not currently pay a regular cash dividend.

When is Arrowhead Pharmaceuticals's next earnings date?

Arrowhead Pharmaceuticals is expected to report earnings on Tuesday, November 24, 2026. Analysts expect EPS of $-1.59.

Who is Arrowhead Pharmaceuticals's CEO?

Dr. Christopher R. Anzalone Ph.D. is the chief executive officer of Arrowhead Pharmaceuticals Inc., which has about 1,062 employees.

Has ARWR ever split its stock?

Yes. The most recent ARWR stock split was a 1-for-10 split on Nov 17, 2011, one of 2 splits on record.

What is the ARWR 52-week high?

The 52-week high for ARWR is $95.49 and the 52-week low is $40.43. The stock is currently 56.7% below its high.

Compare ARWR